Compugen Ltd (CGEN)

$2.11 -0.06 (-2.76%)
Market Cap 193.65M
Revenue (ttm) 72.76M
Net Income (ttm) 35.34M
EPS (ttm) N/A
PE Ratio 6.14
Forward PE N/A
Profit Margin 48.57%
Debt to Equity Ratio 0.00
Volume 184,600
Avg Vol 414,208
Day's Range N/A - N/A
Shares Out 89.24M
Stochastic %K 25%
Beta 2.90
Analysts Strong Sell
Price Target $5.80

Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of P...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 765 8585
Fax: 972 3 765 8555
Website: cgen.com
Address:
Azrieli Center, Building D 26 Harokmim Street, Holon, Israel
KoalaFlipper
KoalaFlipper Mar. 19 at 10:15 AM
$CGEN momentum is adding up and high volumes..
1 · Reply
TwitteringTom
TwitteringTom Mar. 18 at 2:57 PM
$CGEN why the flipping sell off COM ON
0 · Reply
TwitteringTom
TwitteringTom Mar. 17 at 5:52 PM
$CGEN just cant seem to blast past 2.30
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 17 at 2:59 PM
$CGEN Analyst Price Targets 4,00 5.80 Average 13.00 High, they beat esp 60%. the volume is adding up and Volatility 5.56% - 7.09%... if everything goes well we might se a breakout.
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 16 at 6:57 PM
$CGEN breakout soon?? Financial Triggers Strong earnings beats or revenue growth can fuel momentum; CGEN's Q4 2025 results showed $72.8M full-year revenue (up from $27.9M in 2024), despite ongoing losses. Analyst upgrades or buy ratings from all covering firms have previously led to 5%+ daily gains amid sector volatility
1 · Reply
TwitteringTom
TwitteringTom Mar. 16 at 6:27 PM
$CGEN launc
0 · Reply
TwitteringTom
TwitteringTom Mar. 16 at 5:06 PM
$CGEN begging to go higher ......
0 · Reply
AGC_Trader
AGC_Trader Mar. 13 at 2:18 PM
$CGEN I am curious to see what it is going to do at $2.38 this time...
1 · Reply
TwitteringTom
TwitteringTom Mar. 13 at 12:04 PM
$CGEN LETS GO !!!! MOON TIME MOON TIME
0 · Reply
HuntingBenjmins
HuntingBenjmins Mar. 11 at 2:32 PM
$CGEN Still doing pretty good here. If it gets above $2.40 and holds it will have my attention. With the kind of financial status this company has, I’m still shocked it’s not over $5.
0 · Reply
Latest News on CGEN
Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Mar 2, 2026, 2:35 PM EST - 17 days ago

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Mar 2, 2026, 11:17 AM EST - 17 days ago

Compugen Ltd. (CGEN) Q4 2025 Earnings Call Transcript

Compugen Reports Fourth Quarter and Full Year 2025 Results

Mar 2, 2026, 7:00 AM EST - 17 days ago

Compugen Reports Fourth Quarter and Full Year 2025 Results

Compugen to Participate in Upcoming Investor Conferences

Feb 19, 2026, 7:00 AM EST - 4 weeks ago

Compugen to Participate in Upcoming Investor Conferences

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Feb 17, 2026, 7:00 AM EST - 4 weeks ago

Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Feb 12, 2026, 7:00 AM EST - 5 weeks ago

Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Dec 17, 2025, 7:00 AM EST - 3 months ago

Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million

Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:51 AM EST - 4 months ago

Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript

Compugen Reports Third Quarter 2025 Results

Nov 10, 2025, 7:00 AM EST - 4 months ago

Compugen Reports Third Quarter 2025 Results

Compugen to Participate in Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 4 months ago

Compugen to Participate in Stifel 2025 Healthcare Conference

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Oct 27, 2025, 7:00 AM EDT - 5 months ago

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Oct 13, 2025, 7:00 AM EDT - 5 months ago

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen to Present at SITC 2025

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Compugen to Present at SITC 2025

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Compugen to Present Research at the Single Cell Genomics 2025 Conference

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 7:00 AM EDT - 7 months ago

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Aug 8, 2025, 5:13 AM EDT - 8 months ago

Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:30 AM EDT - 8 months ago

Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Compugen Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 8 months ago

Compugen Reports Second Quarter 2025 Results

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Jul 28, 2025, 7:00 AM EDT - 8 months ago

Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Jul 23, 2025, 7:00 AM EDT - 8 months ago

Compugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Jun 12, 2025, 7:00 AM EDT - 10 months ago

Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

May 19, 2025, 10:21 AM EDT - 10 months ago

Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript

Compugen Reports First Quarter 2025 Results

May 19, 2025, 7:00 AM EDT - 10 months ago

Compugen Reports First Quarter 2025 Results

Compugen Announces Leadership Transitions Effective September 2025

May 13, 2025, 7:00 AM EDT - 11 months ago

Compugen Announces Leadership Transitions Effective September 2025

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

May 5, 2025, 7:00 AM EDT - 11 months ago

Compugen to Release First Quarter 2025 Results on Monday, May 19, 2025

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 10:34 AM EST - 1 year ago

Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript

Compugen Reports Fourth Quarter and Full Year 2024 Results

Mar 4, 2025, 7:00 AM EST - 1 year ago

Compugen Reports Fourth Quarter and Full Year 2024 Results

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Mar 3, 2025, 7:00 AM EST - 1 year ago

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Feb 26, 2025, 7:00 AM EST - 1 year ago

Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 18, 2025, 7:00 AM EST - 1 year ago

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Feb 18, 2025, 6:11 AM EST - 1 year ago

Compugen: Immuno-Oncology Innovator Poised For A Comeback

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 7:00 AM EST - 1 year ago

Compugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Jan 8, 2025, 7:00 AM EST - 1 year ago

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG Antibodies

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:35 PM EST - 1 year ago

Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript

Compugen Reports Third Quarter 2024 Results

Nov 12, 2024, 7:00 AM EST - 1 year ago

Compugen Reports Third Quarter 2024 Results

Compugen to Participate in Stifel 2024 Healthcare Conference

Nov 11, 2024, 7:00 AM EST - 1 year ago

Compugen to Participate in Stifel 2024 Healthcare Conference

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Compugen to Present New Clinical Data at SITC 2024

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present New Clinical Data at SITC 2024

Compugen to Present at Single Cell Genomics 2024 Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Single Cell Genomics 2024 Conference

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 5:54 AM EDT - 1 year ago

Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript

Compugen Reports Second Quarter 2024 Results

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Compugen Reports Second Quarter 2024 Results

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024

Compugen to Present at Upcoming Antibody Industrial Symposium

Jun 17, 2024, 7:00 AM EDT - 1 year ago

Compugen to Present at Upcoming Antibody Industrial Symposium

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

May 30, 2024, 7:00 AM EDT - 1 year ago

Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig

AZN

KoalaFlipper
KoalaFlipper Mar. 19 at 10:15 AM
$CGEN momentum is adding up and high volumes..
1 · Reply
TwitteringTom
TwitteringTom Mar. 18 at 2:57 PM
$CGEN why the flipping sell off COM ON
0 · Reply
TwitteringTom
TwitteringTom Mar. 17 at 5:52 PM
$CGEN just cant seem to blast past 2.30
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 17 at 2:59 PM
$CGEN Analyst Price Targets 4,00 5.80 Average 13.00 High, they beat esp 60%. the volume is adding up and Volatility 5.56% - 7.09%... if everything goes well we might se a breakout.
0 · Reply
KoalaFlipper
KoalaFlipper Mar. 16 at 6:57 PM
$CGEN breakout soon?? Financial Triggers Strong earnings beats or revenue growth can fuel momentum; CGEN's Q4 2025 results showed $72.8M full-year revenue (up from $27.9M in 2024), despite ongoing losses. Analyst upgrades or buy ratings from all covering firms have previously led to 5%+ daily gains amid sector volatility
1 · Reply
TwitteringTom
TwitteringTom Mar. 16 at 6:27 PM
$CGEN launc
0 · Reply
TwitteringTom
TwitteringTom Mar. 16 at 5:06 PM
$CGEN begging to go higher ......
0 · Reply
AGC_Trader
AGC_Trader Mar. 13 at 2:18 PM
$CGEN I am curious to see what it is going to do at $2.38 this time...
1 · Reply
TwitteringTom
TwitteringTom Mar. 13 at 12:04 PM
$CGEN LETS GO !!!! MOON TIME MOON TIME
0 · Reply
HuntingBenjmins
HuntingBenjmins Mar. 11 at 2:32 PM
$CGEN Still doing pretty good here. If it gets above $2.40 and holds it will have my attention. With the kind of financial status this company has, I’m still shocked it’s not over $5.
0 · Reply
kshonstocks
kshonstocks Mar. 11 at 2:09 PM
$CGEN has super ibd https://research.investors.com/stock-quotes/nasdaq-compugen-cgen.htm
0 · Reply
wenmoon_stonks
wenmoon_stonks Mar. 10 at 8:32 PM
$CGEN nice come back today. Let's keep it going 🚀💪
0 · Reply
TwitteringTom
TwitteringTom Mar. 10 at 6:36 PM
$CGEN blown
0 · Reply
TwitteringTom
TwitteringTom Mar. 10 at 2:17 PM
$CGEN why cant we bust higher? was 6000 precent earnings beating not good enough? maybe we need to miss expectations tesla style to get movements
0 · Reply
TwitteringTom
TwitteringTom Mar. 9 at 3:08 PM
$CGEN LETS GOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO
0 · Reply
TwitteringTom
TwitteringTom Mar. 6 at 4:27 PM
$CGEN whatya say whaya got, we going to take off... about time!
0 · Reply
Everest17
Everest17 Mar. 6 at 1:20 PM
$CGEN Don’t make me buy more of you.
0 · Reply
TwitteringTom
TwitteringTom Mar. 5 at 2:58 PM
$CGEN we just gonna get stuck here at 2$
0 · Reply
BillionerOfKing
BillionerOfKing Mar. 5 at 2:54 AM
$CGEN Current Stock Price: $2.13 Contracts to trade: $2.5 CGEN Mar 20 2026 Call Entry: $0.05 Exit: $0.06 ROI: 27% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
TwitteringTom
TwitteringTom Mar. 4 at 6:39 PM
$CGEN come on LETS BLAST , COME ON LETS GO
0 · Reply
wenmoon_stonks
wenmoon_stonks Mar. 3 at 9:13 PM
$CGEN added after hours . I believe That was an algo in the last few minutes. $145 mil in cash $188 mil MC They made more money than the difference last q. Today's dip doesn't make sense.
0 · Reply
TwitteringTom
TwitteringTom Mar. 3 at 9:05 PM
$CGEN one would of guessed even with all the market turmoil, this would of kept the earnings movement
1 · Reply